Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
Sponsor: Pfizer
Summary
The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition where a person has too much body fat, which can harm their health and increase the risk of other medical problems. Some people in this study may also have type 2 diabetes, a condition in which the body does not use insulin properly, causing blood sugar levels to become too high. This study is seeking participants in Japan who: * Have obesity disease. * May have type 2 diabetes. * Meet the study-specific age, weight and health requirements. About 180 adults will take part in this study. Participants will be randomly assigned to receive either berobenatide or a placebo. A placebo looks like the study medicine but does not contain any active medicine. Berobenatide or placebo will be given as an injection under the skin of the abdomen (belly area). The study will compare the experiences of people receiving berobenatide with those receiving placebo to determine whether berobenatide can help people lose weight. The study will also assess the safety of berobenatide and its effects on body weight and other health measures. People will take part in this study for about 22 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.
Official title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JW)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2026-10-02
Completion Date
2029-03-14
Last Updated
2026-10-15
Healthy Volunteers
No
Conditions
Interventions
Berobenatide
Solution for injection
Placebo
Solution for injection
Locations (34)
Tokuyama Clinic
Chiba, Chiba, Japan
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
Matsuyama, Ehime, Japan
Matsuyama Shimin Hospital
Matsuyama, Ehime, Japan
Tenjin Sogo Clinic
Fukuoka, Fukuoka, Japan
Medical Corporation BOOCS BOOCS CLINIC FUKUOKA
Fukuoka, Fukuoka, Japan
Oishi Clinic
Kasuya-gun, Fukuoka, Japan
Manda Memorial Hospital
Sapporo, Hokkaido, Japan
Yamasaki Family Clinic
Amagasaki, Hyōgo, Japan
Minami Akatsuka Clinic
Mito, Ibaraki, Japan
Nishiyamado Keiwa Hospital
Naka, Ibaraki, Japan
Olive Takamatsu Medical Clinic
Takamatsu, Kagawa-ken, Japan
Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic
Yokohama, Kanagawa, Japan
Yokoi Clinic
Minoh, Osaka, Japan
Kanemura Clinic
Osaka-shi Ikuno-ku, Osaka, Japan
Medical Corporation Heishinkai OCROM Clinic
Suita, Osaka, Japan
MI Clinic, Medical Corporation Jinsenkai
Toyonaka-shi, Osaka, Japan
Soka Sugiura Internal medicine Clinic
Soka-shi, Saitama, Japan
Doujin Memorial Foundation Meiwa Hospital
Chiyoda-ku, Tokyo, Japan
AIC Yaesu Clinic
Chuo-ku, Tokyo, Japan
Aic Yaesu Clinic
Chuo-ku, Tokyo, Japan
Tokyo Center Clinic
Chuo-ku, Tokyo, Japan
Tokyo-Eki Center-building Clinic
Chuo-ku, Tokyo, Japan
Fukuwa Clinic
Chuo-ku, Tokyo, Japan
Tokyo Asbo Clinic
Chuo-ku, Tokyo, Japan
Medical Corp. Seikoukai New Medical Research System Clinic
Hachioji-shi, Tokyo, Japan
Hachioji Clinic Shincho
Hachioji-shi, Tokyo, Japan
Keikokai Medical Corporation P-one Clinic
Hachiōji, Tokyo, Japan
Patient First Clinic Ginza-Shimbashi
Minato-ku, Tokyo, Japan
Shimamura Memorial Hospital
Nerima-ku, Tokyo, Japan
Medical Corporation Heishinkai ToCROM Clinic
Shinjuku-ku, Tokyo, Japan
Seeds Clinic Shinjuku-Sanchome, Eijinkai Medical Corporation
Shinjuku-ku, Tokyo, Japan
Higashi-Shinjuku Clinic, Keikokai Medical Corp.
Shinjuku-ku, Tokyo, Japan
Ikebukuro Metropolitan Clinic
Toshima-ku, Tokyo, Japan
Nihonbashi Sakura Clinic
Tokyo, Japan